These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31749075)

  • 1. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
    Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
    Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
    Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
    J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elagolix: First Global Approval.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
    Abbas Suleiman A; Nader A; Winzenborg I; Beck D; Polepally AR; Ng J; Noertersheuser P; Mostafa NM
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):639-648. PubMed ID: 32945631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
    Winzenborg I; Nader A; Polepally AR; Liu M; Degner J; Klein CE; Mostafa NM; Noertersheuser P; Ng J
    Clin Pharmacokinet; 2018 Oct; 57(10):1295-1306. PubMed ID: 29476499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
    Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
    Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
    Stodtmann S; Nader A; Polepally AR; Suleiman AA; Winzenborg I; Noertersheuser P; Ng J; Mostafa NM; Shebley M
    Clin Transl Sci; 2021 Jul; 14(4):1611-1619. PubMed ID: 33963686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
    Ng J; Duan WR; Marbury T; Schmidt JM; Klein CE
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1053-1061. PubMed ID: 30570832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
    Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
    N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
    Med Lett Drugs Ther; 2018 Sep; 60(1556):158-160. PubMed ID: 30383729
    [No Abstract]   [Full Text] [Related]  

  • 11. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
    Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
    J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
    Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
    J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
    Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
    Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of elagolix in the treatment of endometriosis.
    Perricos A; Wenzl R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.
    Archer DF; Ng J; Chwalisz K; Chiu YL; Feinberg EC; Miller CE; Feldman RA; Klein CE
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31650182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
    Winzenborg I; Polepally AR; Nader A; Mostafa NM; Noertersheuser P; Ng J
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):466-475. PubMed ID: 32621325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
    Fantasia HC
    Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
    Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
    Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
    Taylor HS; Dun EC; Chwalisz K
    Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
    Chiney MS; Ng J; Gibbs JP; Shebley M
    Clin Pharmacokinet; 2020 May; 59(5):617-627. PubMed ID: 31713224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.